| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
Favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of CRS-associated cytokines observed at any dose level
Cleared fifth of six monotherapy cohorts and second of four combination cohorts
Kineta is actively exploring strategic alternatives to maximize value for all stakeholders
Received $500,000 investment from an existing investor
Posted In: KA
